SeqOmics Ltd is an SME established in 2009 by 4 independent scientists to combine their complementary expertise for occupying an empty niche in the Hungarian, Central/Eastern European biotech industry: genomics based biotechnology. Beside metagenomics based industrial enzyme development and biomarker discovery for clinics, Seqomics provides next generation sequencing (NGS), more precisely massively parallel short read sequencing, which approach proved to be exceptionally powerful in re-sequencing projects (genotyping, biomarker discovery by identifying relevant SNP-s, indels, chromosomal rearrangements) and in expression profiling on digital way (whole transcriptome analysis, SAGE applications, microRNA profiling and discovery). These applications are SeqOmics' top-ranked and most highly demanded NGS services. The company is equipped or has access to the whole sequencing portfolio of Life Technologies such as the Personal Genome Machine.
Role within the project
SeqOmics will lead WP2, participates in WPs 2; 3; 8. The company will capture and sequence the human exome from the samples collected from patients with cervical cancer. With the analysis of the sequence data, it will identify the common driver mutations associated with cervical cancer and will classify the samples into molecular sub-groups should they exist. From the molecular data, it will develop cervical cancer diagnostics panel”, PCR-based or/and for the Personal Genome Machine.